Synovial Sarcoma Treatment Market is expected to be valued at USD 1.1 Billion by 2027 at CAGR of 7.7% | Coherent Market Insights
Synovial Sarcoma Treatment Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Synovial Sarcoma Treatment Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.
Global Synovial Sarcoma Treatment Market Analysis
Synovial sarcoma is characterized by aberrant soft-tissue development. Synovial sarcoma is an uncommon malignancy that affects mostly teens and young adults. Synovial sarcoma is highly metastatic and spreads to other organs in about half of cases, with the lungs being the most frequent occurrence of metastasis. Synovial sarcoma is yet to be determined, however, it has been linked to chromosomal X and chromosome 18 abnormalities in tumor cells. Monophasic and Biphasic synovial sarcomas, as well as poorly differentiated synovial sarcomas, are categorized based on the kind of cells involved. Imaging of the afflicted region, biopsy, gene sequencing, and bone scans are all used to diagnose synovial sarcoma. Depending on the severity of the patient’s illness, treatment for synovial sarcoma might range from medicine to surgery. If the tumor has clean borders and can be removed with healthy tissue, surgery may be considered.
According to the American Cancer Society, the number of people diagnosed with synovial sarcoma in the U.S. in 2018 is anticipated to be 13,040, with 7,370 men and 5,670 women. Increasing R&D in this sector for the discovery of novel treatments for the management of synovial sarcoma is projected to drive the global synovial sarcoma treatment market growth during the forecast period. For instance, Immune Design, Advenchen Laboratories, LLC, Accuronix Therapeutics, and Cue Biopharma are focusing on developing new immunotherapy candidates for the therapy of synovial sarcoma. ACXT-3102, a small molecule drug conjugate developed by Accuronix Therapeutics, is under preclinical research for the cure of synovial sarcoma and other malignancies. AL3818 (anlotinib) is being tested in Phase 3 clinical studies by Advanchen Laboratories for the treatment of synovial sarcoma (SS) and other indications. CMB305, an antigen-specific prime boost, is in Phase II clinical studies for synovial sarcoma at Immune Design. CUE-102, a possible therapy for melanoma, synovial sarcoma, thyroid, and head and neck cancers, is being developed by Cue Biopharma.
In addition, research on new vaccinations for the treatment of synovial sarcoma is underway, which might expand synovial sarcoma therapy choices. During the forecast period, these aspects are projected to propel the global synovial sarcoma treatment market forward.
The growth of the global synovial sarcoma treatment market is projected to be hampered by side effects associated with cancer therapy, high prices, and the unpredictability of clinical trial outcomes during the forecast period.
Get Flat USD 2000 OFF
Buy-Now this research report: https://www.coherentmarketinsights.com/promo/buynow/1571
Due to research and development efforts, as well as the high frequency of synovial sarcoma, North America is anticipated to increase significantly throughout the forecast period. Immunotherapy is a prominent therapeutic option in the region, with immunotherapies including checkpoint inhibitors and adoptive T cell therapy being investigated for the treatment of synovial sarcoma. At the 2017 Connective Tissue Oncology Society Annual Meeting, encouraging results from phase 2 trials of the conjunction of Axitinib and Pembrolizumab in the patients with locally advanced alveolar soft part sarcoma and other soft tissue sarcomas were reported. Furthermore, the existence of novel biotech firms like Immunocore, who are constantly involved in the research and development of targeted treatments like ImmTAC, is expected to boost progress in the European market.
Major companies contributing in the global synovial sarcoma treatment market are F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Genentech USA, Pfizer, Inc., Celgene Corporation, Eli Lilly and Company, Teva Pharmaceuticals, Bristol-Myers Squibb, and Johnson & Johnson.
Synovial Sarcoma Treatment Market Taxonomy-
The global synovial sarcoma treatment market is segmented on the basis of treatment type, end user, and geography.
By Treatment Type-
- Anti-Angiogenesis Drugs
By End User-
- Oncology Centers
- North America
- Asia Pacific
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire